Clinical Trials | Randomized Phase 2/3 Trial of NP-G2-044 Combined with PLD for Treatment of Platinum-Resistant Ovarian Cancer
Randomized Phase 2/3 Trial of NP-G2-044 Combined with PLD for Treatment of Platinum-Resistant Ovarian Cancer
The University of Virginia is looking for women aged 18 and older to take part in a clinical trial. You may be able to participate if you have platinum-resistant high grade serous ovarian cancer and have either been treated with a drug called bevacizumab in the past or were told you were ineligible to receive it. This study will test the optimal dose level of a medication called NP-G2-44 in combination with a standard of care medication called pegylated liposomal doxorubicin (PLD). This study will include: blood draws, electrocardiograms (ECGs), echocardiograms (ECHO) or multigated acquisition (MUGA), tumor imaging assessments, questionnaires, and physical examinations. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. More information can be found here: https://clinicaltrials.gov/study/NCT07109414